Managing long QT syndrome patients, cooking, and common sense
Open Access
- 19 February 2025
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 27 (Supplement) , i47-i50
Abstract
This essay stems from a controversial recommendation present in the 2022 European Guidelines which indicated the appropriateness of considering an implantable cardioverter defibrillator (ICD) implant even for still asymptomatic long QT syndrome (LQTS) patients deemed to be at high risk by the 1–2–3 LQTS score based on QTc and genotype calculated prior to the institution of therapy. As 15 years ago, we also had proposed, but never used, a risk score called M-FACT to identify patients at high risk of an appropriate ICD shock, we felt the responsibility of assessing what would have happened to our patients if we had rigorously used that score. We performed a study recently published in the European Heart Journal which brought to general attention two concepts important for clinical management. One is that all LQTS patients should be seen at least once a year for a reassessment of arrhythmic risk based on standard electrocardiogram, 12-lead 24 h Holter recording and an exercise stress test. The other is that, based on these yearly visits, we perform ‘therapy optimization’ by adding to the standard β-blocker therapy either left cardiac sympathetic denervation or mexiletine or an ICD implant. On almost 1000 LQTS patients, all genotyped, this dynamic approach was accompanied by not a single death, few events, and out of 142 patients who should have received an ICD based on the score, only 22 did and only 3 had an ICD shock. These data and concepts call for a reconsideration of the recommendation made by the guidelines.Keywords
Funding Information
- Italian Ministry of Health Ricerca Corrente ‘Registro delle Canalopatie Cardiache’
This publication has 14 references indexed in Scilit:
- 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathEuropean Heart Journal, 2022
- Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?European Heart Journal, 2022
- Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmiasEuropean Heart Journal, 2022
- Left Cardiac Sympathetic Denervation for Long QT SyndromeJACC: Clinical Electrophysiology, 2022
- Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk)EP Europace, 2021
- Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT SyndromeJACC, 2018
- Cardiac sympathetic denervation to prevent life-threatening arrhythmiasNature Reviews Cardiology, 2014
- Not All Beta-Blockers Are Equal in the Management of Long QT Syndrome Types 1 and 2JACC, 2012
- Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?Circulation, 2010
- Long QT Syndrome Patients With Mutations of the SCN5A and HERG Genes Have Differential Responses to Na + Channel Blockade and to Increases in Heart RateCirculation, 1995